Overall, our work revealed a strong positive correlation between BRD4 overexpression status and chemoresistance in ovarian cancer, which could be explored to develop a prognostic strategy to predict a patient response to platinum/taxane-based chemotherapy. The gene discussed is BRD4; the disease is ovarian cancer.